Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K(2020) Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study Acta Oncol, 1-8(in press) DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
Bell L, Holloway L, Bruheim K, Petrič P, Kirisits C, Tanderup K, Pötter R, Vinod S, Lim K, Pogson E, Metcalfe P, Hellebust TP(2020) Dose planning variations related to delineation variations in MRI-guided brachytherapy for locally advanced cervical cancer Brachytherapy, 19(2), 146-153 DOI 10.1016/j.brachy.2020.01.002, PubMed 32067884
Palmer DH, Valle JW, Ting Ma Y, Faluyi O, Neoptolemos JP, Jensen Gjertsen T, Iversen B, Amund Eriksen J, Møller AS, Aksnes AK, Miller R, Dueland S(2020) TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial Br J Cancer, 122(7), 971-977 DOI 10.1038/s41416-020-0752-7, PubMed 32063605
